Acrivon Therapeutics, Inc. 8-K

What Happened Acrivon Therapeutics, Inc. announced its financial results and business updates for the quarter ended March 31, 2026 via a press release issued May 13, 2026. The company furnished that press release as Exhibit 99.1 to its Current Report on Form 8-K (filed May 13, 2026), which is the public source for the reported quarterly results and operational information. The filing was signed by President and CEO Peter Blume-Jensen, M.D., Ph.D.

Key Details

• Filing date: May 13, 2026 (Form 8-K, Item 2.02 Results of Operations and Financial Condition).
• Reporting period: Quarter ended March 31, 2026.
• Exhibit: Press release dated May 13, 2026 furnished as Exhibit 99.1 to the 8-K.
• Signature: Report signed on behalf of the company by CEO Peter Blume-Jensen, M.D., Ph.D.

Why It Matters This 8-K signals that Acrivon has publicly released its quarterly financial results and associated operational updates; investors should review the furnished press release (Exhibit 99.1) for specific figures on revenue, expenses, cash position, guidance, or program progress. Because the 8-K itself references the press release as the source of the results, that exhibit is the primary document to consult for any immediate investment decisions or to assess the company’s near-term financial and clinical outlook.